Best Practices - Focus on CNS Pharma deals: How to pull in the money
SESSION THEMESGardiner Smith, partner in SHI Link and former Chief Business Officer of Memory Pharmaceuticals, will provide an overview of recent CNS deals that have exceeded pharma industry expectations. Drawing on personal experience, he will also discuss the intricacies of partnering high-risk products. During his tenure at Memory, Gardiner led three preclinical stage deals that had a combined upfront payment value of over $60 M US, which allowed the company to go public. Currently, at SHI Link he is engaged in out-licensing a Phase 2 neurodegenerative product and a Phase 3 pain product. Come and join us for a insightful presentation and discussion. |  |
SPEAKER
Gardiner Smith, Executive Vice-President, Strategic Transactions SHI-LinkDATE | TIME | LOCATION
December 12, 200711:00AM - 1:00PM
(Participants are welcome to bring their lunch)
MaRS Auditorium - A
101 College St, Toronto
REGISTRATION
General Registration: $20Student Registration: Free
Registration is now closed.
DOWNLOADS AND RESOURCES
- Download the Presentation: Focus on CNS Pharma deals
"How to pull in the money"
- View the presentation below.
ABOUT THE SPEAKER
Building on executive operating roles in leading pharma and biotech companies for over a decade, Gardiner is focused on consummating major transactions which span creative alliance structures, stages of development and a variety of technology innovations. In addition to leading over a dozen successful transactions between biotech and pharma companies, including with Human Genome Sciences, Memory Pharmaceuticals, Roche, GSK and Amgen, he has led the execution of an equal number of biotech-biotech alliances between product, antibody, and platform companies such as Affymetrix and Cambridge Antibody Technologies. The total potential up front and milestone value of buy-side and sell-side transactions in which he's had a leading role in over the last ten years exceeds $750 MM, excluding royalties. Additionally, he has been part of the transaction team for large acquisitions, such as the Glaxo purchase of Affymax for $530 MM.UPCOMING EVENTS
PAST EVENTS
- October 9, 2008
Best Practices: Is Your Business Model Creative? - June 3, 2008
MaRS Best Practices Series - Good Laboratory Practices - May 13, 2008
MaRS Best Practices Series - From bench top to IND - April 24, 2008
MaRS Best Practices Series - IP Strategies for Medical Devices - April 7, 2008
MaRS Best Practices Series - Doing Business with the National Institutes of Health (NIH): Opportunities for industry - March 29, 2008
MaRS Best Practices Series - How to Draft a Patent Application - March 20, 2008
MaRS Best Practices Series - IP Strategies for Therapeutics - February 28, 2008
MaRS Best Practices Series - IP Strategies for Diagnostics - February 23, 2008
MaRS Best Practices Series - How to Draft a Patent Application - December 12, 2007
MaRS Best Practices Series - Focus on CNS Pharma deals: How to pull in the money - May 23, 2007
MaRS Best Practices Series - Pre-Clinical development workshop - MaRS Best Practices Series - Asymmetric Communications: Building Momentum through Non-Traditional Marketing
- April 11, 2007
MaRS Best Practices Series - Intellectual Property and Valuation of Emerging Medical Therapeutics - November 21, 2006
MaRS Best Practices Series - Business, Science, Technology and You: Financing R&D through Canada’s SR&ED Program - November 9, 2006
MaRS Best Practices Series - Introduction to Systems Biology - September 14, 2006
MaRS Best Practices Series - From Bench to Headline: Translating science for the media - September 8, 2006
MaRS Besst Practices Series - The Power of Pictonics: Using visualizations to tell your technology story - July 12, 2006
MaRS Best Practices Series - Why commercializing a technology is really, really hard to do - May 17, 2006
MaRS Best Practices Series - So what? Who cares? Why you? - April 5, 2006
MaRS Best Practices Series - The move toward drug development - February 11, 2006
MaRS Best Practices Series - How To Draft a Patent Application - February 9, 2006
MaRS Best Practices Series - New Technologies for Accelerating Drug Development
